<p>Costs and QALYs gained per 1,000 participants, compared to no screening. QALY: quality adjusted life year; gFOBT: guaiac fecal occult blood test; FIT: fecal immunochemical test; Col/year: number of colonoscopies required per 1,000 participants per year. Strategies are varying by age at starting screening, age at stopping screening, screening interval, and FIT cut-off level. For each level of available colonoscopy capacity (maximal 17, 20, 30, 40 colonoscopies per 1,000 participants per year and unrestricted colonoscopy capacity) the cost-effective strategies are connected by their respective efficient frontier. The text boxes beside each frontier present the screening strategy (test, age range, interval and colonoscopy</p
International audienceObjective: To assess the cost-effectiveness of colorectal cancer screening usi...
BACKGROUND & AIMS: Biomarker assays could increase the accuracy of noninvasive detection of colo...
This study aimed to examine the cost-effectiveness of fecal biomarker M3 panel compared to fecal imm...
Fecal occult blood testing (FOBT) can be adapted to a limited colonoscopy capacity by narrowing the ...
Background & Aims: Two European randomized trials (N = 30,000) compared guaiac fecal occult blood te...
BACKGROUND: Fecal occult blood testing (FOBT) can be adapted to a limited colonoscopy capacity by na...
The ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada, is considerin...
BackgroundThe ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada, is ...
Objectives In 2016, it was announced that the fecal immunochemical test (FIT) would replace the g...
Background and Aims: To determine the cost-effectiveness of screening for colorectal cancer using f...
Inadequate bowel preparation during screening colonoscopy necessitates repeating colonoscopy. Studie...
Inadequate bowel preparation during screening colonoscopy necessitates repeating colonoscopy. Studie...
Background: Organised programmes for colorectal cancer screening demand a high burden of medical and...
Objectives Through the National Health Service Bowel Cancer Screening Programme (BCSP), men and wome...
Background: Colorectal cancer screening can decrease morbidity and mortality. However, there are wid...
International audienceObjective: To assess the cost-effectiveness of colorectal cancer screening usi...
BACKGROUND & AIMS: Biomarker assays could increase the accuracy of noninvasive detection of colo...
This study aimed to examine the cost-effectiveness of fecal biomarker M3 panel compared to fecal imm...
Fecal occult blood testing (FOBT) can be adapted to a limited colonoscopy capacity by narrowing the ...
Background & Aims: Two European randomized trials (N = 30,000) compared guaiac fecal occult blood te...
BACKGROUND: Fecal occult blood testing (FOBT) can be adapted to a limited colonoscopy capacity by na...
The ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada, is considerin...
BackgroundThe ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada, is ...
Objectives In 2016, it was announced that the fecal immunochemical test (FIT) would replace the g...
Background and Aims: To determine the cost-effectiveness of screening for colorectal cancer using f...
Inadequate bowel preparation during screening colonoscopy necessitates repeating colonoscopy. Studie...
Inadequate bowel preparation during screening colonoscopy necessitates repeating colonoscopy. Studie...
Background: Organised programmes for colorectal cancer screening demand a high burden of medical and...
Objectives Through the National Health Service Bowel Cancer Screening Programme (BCSP), men and wome...
Background: Colorectal cancer screening can decrease morbidity and mortality. However, there are wid...
International audienceObjective: To assess the cost-effectiveness of colorectal cancer screening usi...
BACKGROUND & AIMS: Biomarker assays could increase the accuracy of noninvasive detection of colo...
This study aimed to examine the cost-effectiveness of fecal biomarker M3 panel compared to fecal imm...